Lubiprostone

Also known as AMITIZA.

Latest news on lubiprostone

5 June 2026
Takeda revises FY2025 results after AMITIZA® antitrust verdict

Recorded JPY 402.5bn legal provision and JPY 58.4bn tax benefit; core results and FY2026 guidance unchanged. Company will appeal and seek a stay; district court action expected H2 2026.

19 May 2026
Takeda: Jury verdict in AMITIZA antitrust case; FY2025 results to be revised

Jury awarded USD 884,943,990 in single damages in AMITIZA antitrust trial; wholesaler/retailer sums subject to trebling. Will appeal, assess provision and revise FY2025 filings; minimal FY2026 impact.